New hope for kids: drug combo may stop transplant rejection
NCT ID NCT03924401
First seen Mar 12, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tests whether adding abatacept to standard medications can prevent graft-versus-host disease (GVHD) in 30 children and teens receiving stem cell transplants from unrelated donors for serious blood disorders. GVHD is a dangerous complication where donor cells attack the patient's body. Participants will receive abatacept alongside standard drugs and be followed for up to 3 years to see if this approach improves survival without severe GVHD or graft rejection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST-DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
-
Children's of Alabama
Birmingham, Alabama, 35233, United States
-
Childrens Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hackensack Meridian Health
Hackensack, New Jersey, 07601, United States
-
Nemours/Alfred I. DuPont Hospital for Children
Wilmington, Delaware, 19803, United States
-
Oishei Children's Hospital
Buffalo, New York, 14203, United States
-
University of Mississippi Medical Center, Children's Center for Cancer and Blood Disorders
Jackson, Mississippi, 39216, United States
Conditions
Explore the condition pages connected to this study.